Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$4.12B |
| 2 |
Gilead Sciences
GILD
|
+$379M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$286M |
| 4 |
Amazon
AMZN
|
+$271M |
| 5 |
Meta Platforms (Facebook)
META
|
+$266M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$762M |
| 2 |
SPDR Gold Trust
GLD
|
+$410M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$400M |
| 4 |
QIHU
QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS
QIHU
|
+$227M |
| 5 |
Synchrony
SYF
|
+$195M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 2.31% |
| 2 | Technology | 1.26% |
| 3 | Financials | 1.12% |
| 4 | Healthcare | 1.04% |
| 5 | Consumer Discretionary | 0.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
PUT
ProShares Ultra VIX Short-Term Futures ETF
UVXY
$268M
| $166M | 0.08% |
40
+29
| +264% | +$178M |
|
202
PUT
Broadcom
AVGO
$1.75T
| $164M | 0.08% |
9,522,000
-4,770,000
| -33% | -$79.8M |
|
203
PUT
Kinder Morgan
KMI
$69B
| $163M | 0.08% |
7,060,200
+2,225,200
| +46% | +$47.1M |
|
204
PUT
SLB Ltd
SLB
$79.9B
| $161M | 0.08% |
2,050,000
+185,200
| +10% | +$14.7M |
|
205
CALL
Regeneron Pharmaceuticals
REGN
$85.9B
| $161M | 0.08% |
400,000
-400
| -0.1% | -$160K |
|
206
CALL
iShares MSCI Brazil ETF
EWZ
$8.52B
| $160M | 0.08% |
4,737,300
-1,719,800
| -27% | -$56.9M |
|
207
PUT
HCA Healthcare
HCA
$92.9B
| $159M | 0.08% |
2,101,200
+1,132,700
| +117% | +$86.7M |
|
208
PUT
WisdomTree Japan Hedged Equity Fund
DXJ
$7.23B
| $159M | 0.08% |
3,699,300
+1,594,700
| +76% | +$66.2M |
|
209
PUT
Union Pacific
UNP
$183B
| $159M | 0.08% |
1,626,000
+44,700
| +3% | +$4.18M |
|
210
PUT
PepsiCo
PEP
$196B
| $157M | 0.08% |
1,447,700
-367,400
| -20% | -$39.6M |
|
211
PUT
American Airlines Group
AAL
$9.15B
| $157M | 0.08% |
4,298,800
-905,300
| -17% | -$32M |
|
212
CALL
Lockheed Martin
LMT
$130B
| $157M | 0.08% |
653,400
+278,300
| +74% | +$69.7M |
|
213
CALL
Salesforce
CRM
$171B
| $156M | 0.08% |
2,182,900
-486,500
| -18% | -$37.9M |
|
214
PUT
DuPont de Nemours
DD
$18.7B
| $155M | 0.07% |
1,182,432
+680,301
| +135% | +$90.7M |
|
215
PUT
AB InBev
BUD
$155B
| $155M | 0.07% |
1,175,800
+608,900
| +107% | +$76.9M |
|
216
Teva Pharmaceuticals
TEVA
$43.5B
| $154M | 0.07% |
3,344,433
+1,139,241
| +52% | +$59.4M |
|
217
CALL
Bausch Health
BHC
$2.41B
| $154M | 0.07% |
6,263,900
+978,100
| +19% | +$25.3M |
|
218
CALL
FedEx
FDX
$76.9B
| $153M | 0.07% |
876,000
+105,900
| +14% | +$17.3M |
|
|
PXD
219
PUT
DELISTED
Pioneer Natural Resource Co.
PXD
| $152M | 0.07% |
818,700
-178,400
| -18% | -$30.4M |
|
220
PUT
Honeywell
HON
$68.4B
| $151M | 0.07% |
1,442,312
+619,883
| +75% | +$64.8M |
|
221
CALL
ProShares Short VIX Short-Term Futures ETF
SVXY
$251M
| $151M | 0.07% |
2,063,700
-446,500
| -18% | -$29.9M |
|
|
222
CALL
Honeywell
HON
$68.4B
| $151M | 0.07% |
1,440,531
+695,003
| +93% | +$72.6M |
|
223
PUT
Yum! Brands
YUM
$41.8B
| $150M | 0.07% |
2,300,992
+87,772
| +4% | +$5.6M |
|
224
PUT
UnitedHealth
UNH
$350B
| $149M | 0.07% |
1,066,500
+516,500
| +94% | +$72.3M |
|
225
CALL
Morgan Stanley
MS
$336B
| $149M | 0.07% |
4,657,000
+147,000
| +3% | +$4.38M |
|
Similar funds
Jeff Yass's Q3 2016 Portfolio in Review
As of Q3 2016, Jeff Yass held 9,816 positions worth $207B, up 11% from $187B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jeff Yass deployed $7.57B of net new capital in Q3 2016, opening 1,347 new positions and adding to 3,275 existing holdings. Its largest new stake was Bristol-Myers Squibb: 4,459,411 shares worth $240M.
By sector, the portfolio is most concentrated in Consumer Staples at 2.3% of assets, up from 0.28% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Apple, an estimated $762M trimmed.
- Jeff Yass's largest Q3 2016 buy was Bristol-Myers Squibb: 4,459,411 shares worth $240M.
- Jeff Yass added most to Procter & Gamble in Q3 2016, an estimated $4.12B increase.
- Jeff Yass's biggest Q3 2016 reduction was Apple, cutting an estimated $762M.
- Jeff Yass fully exited QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS in Q3 2016, selling an estimated $227M.
- Jeff Yass's ten largest holdings make up 27% of its $207B portfolio in Q3 2016.
- Jeff Yass opened 1,347 new positions and closed 1,488 in Q3 2016.
- Jeff Yass's portfolio value rose 11% quarter-over-quarter to $207B.
Based on Susquehanna International Group's 13F filing for Q3 2016, filed 14 Nov 2016.